However, the presence of miR-143 in tumor tissue may indicate that not all patients were KRAS-positive (KRAS mutations are observed in 40–45% of CRC patients [58] or that the clinical samples were contaminated with KRAS-negative cells. The gene discussed is KRAS; the disease is neoplasm.